MedTrace Logo

Surgery for Pancreatic Cancer With Oligo-Metastasis

NCT04196816 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-12-29

No results posted yet for this study

Summary

Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019).

However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients.

The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer

Conditions

Sponsors & Collaborators

  • Université Montpellier

    collaborator OTHER

  • Association de Chirurgie hepato-bilio-pancreatique et transplantation (ACHBT)

    collaborator UNKNOWN

  • Federation de recherche en chirurgie digestive (FRENCH)

    collaborator UNKNOWN

  • Club Français du Pancreas (CFP)

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • REGIS SOUCHE · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-03-01
Completion
2020-12-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04196816 on ClinicalTrials.gov